Marshak-Rothstein A - Search Results

1

Nucleic Acid-Sensing Receptors: Rheostats of Autoimmunity and Autoinflammation.

Sharma S, Fitzgerald KA, Cancro MP, Marshak-Rothstein A. Sharma S, et al. J Immunol. 2015 Oct 15;195(8):3507-12. doi: 10.4049/jimmunol.1500964. J Immunol. 2015. PMID: 26432899 Free PMC article. Review.

2

The mechanism of autoantibody production in an autoimmune MRL/lpr mouse.

Shan H, Shlomchik MJ, Marshak-Rothstein A, Pisetsky DS, Litwin S, Weigert MG. Shan H, et al. J Immunol. 1994 Dec 1;153(11):5104-20. J Immunol. 1994. PMID: 7525723

3

Fas ligand-mediated cytotoxicity is directly responsible for apoptosis of normal CD4+ T cells responding to a bacterial superantigen.

Ettinger R, Panka DJ, Wang JK, Stanger BZ, Ju ST, Marshak-Rothstein A. Ettinger R, et al. J Immunol. 1995 May 1;154(9):4302-8. J Immunol. 1995. PMID: 7536768

4

Functional distinctions between MRL-lpr and MRL-gld lymphocytes. Normal cells reverse the gld but not lpr immunoregulatory defect.

Ettinger R, Wang JK, Bossu P, Papas K, Sidman CL, Abbas AK, Marshak-Rothstein A. Ettinger R, et al. J Immunol. 1994 Feb 15;152(4):1557-68. J Immunol. 1994. PMID: 8120369

5

IL-4 induces Fas resistance in B cells.

Foote LC, Howard RG, Marshak-Rothstein A, Rothstein TL. Foote LC, et al. J Immunol. 1996 Oct 1;157(7):2749-53. J Immunol. 1996. PMID: 8816375

6

Identification of two NF-kappa B sites in mouse CD95 ligand (Fas ligand) promoter: functional analysis in T cell hybridoma.

Matsui K, Fine A, Zhu B, Marshak-Rothstein A, Ju ST. Matsui K, et al. J Immunol. 1998 Oct 1;161(7):3469-73. J Immunol. 1998. PMID: 9759866

7

Acceleration of lpr lymphoproliferative and autoimmune disease by transgenic protein kinase CK2 alpha.

Rifkin IR, Channavajhala PL, Kiefer HL, Carmack AJ, Landesman-Bollag E, Beaudette BC, Jersky B, Salant DJ, Ju ST, Marshak-Rothstein A, Seldin DC. Rifkin IR, et al. J Immunol. 1998 Nov 15;161(10):5164-70. J Immunol. 1998. PMID: 9820486

8

Immune complexes present in the sera of autoimmune mice activate rheumatoid factor B cells.

Rifkin IR, Leadbetter EA, Beaudette BC, Kiani C, Monestier M, Shlomchik MJ, Marshak-Rothstein A. Rifkin IR, et al. J Immunol. 2000 Aug 1;165(3):1626-33. doi: 10.4049/jimmunol.165.3.1626. J Immunol. 2000. PMID: 10903773

9

CD95 (Fas) ligand-expressing vesicles display antibody-mediated, FcR-dependent enhancement of cytotoxicity.

Jodo S, Hohlbaum AM, Xiao S, Chan D, Strehlow D, Sherr DH, Marshak-Rothstein A, Ju ST. Jodo S, et al. J Immunol. 2000 Nov 15;165(10):5487-94. doi: 10.4049/jimmunol.165.10.5487. J Immunol. 2000. PMID: 11067901

10

Activation-induced cell death limits effector function of CD4 tumor-specific T cells.

Saff RR, Spanjaard ES, Hohlbaum AM, Marshak-Rothstein A. Saff RR, et al. J Immunol. 2004 Jun 1;172(11):6598-606. doi: 10.4049/jimmunol.172.11.6598. J Immunol. 2004. PMID: 15153474

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

188 results

Search Page

Filters